發(fā)布時(shí)間：2018-05-30 10:50

  本文選題：β細(xì)胞 + α細(xì)胞　； 參考：《南方醫(yī)科大學(xué)》2017年碩士論文

【摘要】：[背景]糖尿病患者數(shù)逐年增加,已經(jīng)成為危害公共健康的重大難題,其發(fā)病的中心環(huán)節(jié)是胰島β細(xì)胞數(shù)目減少和功能受損。目前糖尿病的主要治療方式為藥物治療和胰腺移植。由于環(huán)境等因素的影響,移植后的外源性胰腺并不能很好地發(fā)揮調(diào)節(jié)血糖的作用,因此胰島β細(xì)胞的內(nèi)源性增殖成為人們關(guān)注的焦點(diǎn)。目前有研究發(fā)現(xiàn)胰腺外分泌細(xì)胞(胰腺導(dǎo)管細(xì)胞和胰腺腺泡細(xì)胞)以及胰腺外細(xì)胞(肝臟細(xì)胞)可以轉(zhuǎn)化成為胰島β細(xì)胞。在一些β細(xì)胞極端受損的糖尿病動(dòng)物模型中,研究者觀察到α細(xì)胞轉(zhuǎn)化成為β細(xì)胞的現(xiàn)象,為糖尿病的治療帶來了新的思路。既往研究認(rèn)為GLP-1有促進(jìn)β細(xì)胞增生并抑制其凋亡的作用,但其具體機(jī)制尚不明確。有研究表明GLP-1作用于細(xì)胞表面的GLP-1受體,通過PI3K/Akt/FOX01信號(hào)通路增強(qiáng)PDX-1的反應(yīng)性,PDX-1在維持β細(xì)胞形態(tài)功能中起到重要作用,并能促進(jìn)非β細(xì)胞向β細(xì)胞轉(zhuǎn)化。由此我們推測(cè)GLP-1通過細(xì)胞表面GLP-1受體激活細(xì)胞內(nèi)PI3K/Akt/FOXO1信號(hào)通路,調(diào)節(jié)PDX-1、MafA、MafB等轉(zhuǎn)錄因子的表達(dá),繼而促進(jìn)α細(xì)胞跨譜系轉(zhuǎn)化為β細(xì)胞。[目的]本課題擬建立單次大劑量STZ誘導(dǎo)重度β細(xì)胞損傷的糖尿病大鼠模型,通過觀察GLP-1干預(yù)后大鼠胰島中內(nèi)分泌細(xì)胞數(shù)目的變化,探討GLP-1能否促進(jìn)大鼠胰島β細(xì)胞原位再生及其可能的機(jī)制。應(yīng)用GLP-1受體抑制劑和PI3K酶抑制劑對(duì)糖尿病大鼠干預(yù)后,檢測(cè)PI3K/Akt/FOXO1信號(hào)通路相關(guān)信號(hào)因子轉(zhuǎn)錄水平和蛋白表達(dá)水平,探討GLP-1能否通過PI3K/Akt/FOX01信號(hào)通路促進(jìn)α細(xì)胞轉(zhuǎn)化成為β細(xì)胞。[內(nèi)容]內(nèi)容分為以下三大部分:第一部分GLP-1促進(jìn)STZ誘導(dǎo)的糖尿病大鼠胰島β細(xì)胞原位再生目的探討GLP-1能否促進(jìn)胰島β細(xì)胞的原位再生。方法單次大劑量注射STZ建立糖尿病大鼠模型,將空腹血糖值大于28mmol/L的SD大鼠納入研究,并將其分為五組:正常對(duì)照組、糖尿病模型組、GLP-150μg/kg干預(yù)組、GLP-1100μg/kg干預(yù)組、GLP-12000μg/kg干預(yù)組。每周監(jiān)測(cè)各組大鼠血糖、體重變化;ELISA法檢測(cè)C肽、胰島素水平;大鼠胰腺切片insulin/gucagon雙重免疫染色觀察內(nèi)分泌細(xì)胞數(shù)目變化。統(tǒng)計(jì)學(xué)方法為one-way ANOVA,P0.05差異具有統(tǒng)計(jì)學(xué)意義。結(jié)果與糖尿病模型組相比,GLP-1干預(yù)后糖尿病大鼠的血糖水平減低、體重下降;C肽、胰島素水平上升;胰島素分泌細(xì)胞數(shù)目呈GLP-1劑量依賴型增加,差異均具有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論GLP-1能夠促進(jìn)β細(xì)胞原位再生。第二部分GLP-1通過驅(qū)動(dòng)胰島內(nèi)α細(xì)胞轉(zhuǎn)分化為β細(xì)胞促進(jìn)胰島的原位再生及功能重建目的探討GLP-1促進(jìn)β細(xì)胞原位再生的可能機(jī)制。方法分組同第一部分,對(duì)大鼠胰腺冰凍切片行insulin/glucagon、insulin/amylase、insulin/Pan-CK雙重免疫熒光染色,對(duì)大鼠胰腺石蠟切片行PCNA免疫組化染色。統(tǒng)計(jì)學(xué)方法為one-way ANOVA,P0.05差異具有統(tǒng)計(jì)學(xué)意義。結(jié)果GLP-1干預(yù)后,糖尿病大鼠胰島中出現(xiàn)insulin/glucagon雙陽(yáng)性細(xì)胞,數(shù)目隨GLP-1干預(yù)劑量增加而增加,差異具有統(tǒng)計(jì)學(xué)意義(P0.05)。大鼠胰腺切片中未觀察到insulin/amylase、insulin/pan-ck雙陽(yáng)性細(xì)胞;PCNA免疫組化結(jié)果無明顯差異(P0.05),且染色區(qū)域均位于α細(xì)胞分布區(qū)域。結(jié)論GLP-1促進(jìn)β細(xì)胞的原位再生來自于α細(xì)胞的轉(zhuǎn)化,無胰腺腺泡細(xì)胞或?qū)Ч芗?xì)胞的轉(zhuǎn)化,也無α細(xì)胞的自我復(fù)制。第三部分GLP-1及其受體經(jīng)PI3K/Akt/FOXO1通路上調(diào)PDX-1表達(dá)促進(jìn)α細(xì)胞轉(zhuǎn)分化為β細(xì)胞目的探討GLP-1通過其受體經(jīng)PI3K/Akt/FOXO1通路增強(qiáng)轉(zhuǎn)錄因子PDX-1、MafB的表達(dá),下調(diào)MafA的表達(dá),繼而促進(jìn)α細(xì)胞轉(zhuǎn)分化為β細(xì)胞。方法建立糖尿病大鼠模型后,將SD大鼠分為7組:正常對(duì)照組、糖尿病模型組、GLP-1 50μμg/kg 干預(yù)組、GLP-1 100μg/kg 干預(yù)組、GLP-1 200μg/kg 干預(yù)組、GLP-1與GLP-1受體拮抗劑exendin(9-39)共同干預(yù)組、GLP-1與PI3K酶抑制劑 LY294002 共同干預(yù)組。RT-PCR 檢測(cè) GLP-1R、AKT、PDX-1、MafA、MafB、Foxol的mRNA表達(dá)結(jié)果;Western blot檢測(cè)大鼠胰島中GLP-1R、PDX-1、MafA、MafB、Akt的蛋白表達(dá)結(jié)果。結(jié)果PCR結(jié)果顯示:糖尿病模型組的GLP-1R、Akt、PDX-1、FOXO1、MafA、MafB的表達(dá)較正常組明顯下降。GLP-1干預(yù)后,GLP-1R、Akt、PDX-1、FOXOl MafA的mRNA表達(dá)量明顯上升,MafBmRNA表達(dá)量下降,呈劑量依賴型。exendin(9-39)抑制 GLP-1 受體后,GLP-1R、Akt、PDX-1、Foxol、MafA 的mRNA表達(dá)量較GLP-1 100μg/kg干預(yù)組下降,而MafB表達(dá)量上升。LY294002抑制 PI3K 酶后,GLP-1R、Akt、PDX-1、Foxol、MafA 的 mRNA 表達(dá)量較GLP-1100μg/kg干預(yù)下降,而MafB表達(dá)量上升。Western blot結(jié)果與PCR結(jié)果相似,差異均具有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論GLP-1通過GLP-1受體及其下游的PI3K/Akt/FOXO1通路增強(qiáng)轉(zhuǎn)錄因子PDX-1、MafA的表達(dá),下調(diào)MafB的表達(dá),進(jìn)而促進(jìn)α細(xì)胞向β細(xì)胞轉(zhuǎn)化。
[Abstract]:[background] the number of diabetic patients has increased year by year. It has become a major problem endangering public health. The central link of the disease is the decrease of the number of beta cells and impaired function. At present, the main treatment for diabetes is drug treatment and pancreas transplantation. The exogenous pancreas after transplantation is not very good because of the influence of environment and other factors. The endogenous proliferation of islet beta cells has become the focus of attention. Recent studies have shown that pancreatic exocrine cells (pancreatic duct cells and pancreatic acinar cells) and pancreatic cells (liver cells) can be transformed into islet beta cells. In some diabetic animal models with extreme damage to beta cells The researchers have observed that the transformation of alpha cells into beta cells brings new ideas for the treatment of diabetes. Previous studies suggest that GLP-1 has the effect of promoting beta cell proliferation and inhibiting its apoptosis, but its specific mechanism is not clear. Studies have shown that GLP-1 acts on the GLP-1 receptor on the cell surface and increases through the PI3K/Akt/FOX01 signaling pathway. The reaction of strong PDX-1, PDX-1 plays an important role in maintaining the morphologic function of beta cells, and can promote the transformation of non beta cells to beta cells. Therefore, we speculate that GLP-1 regulates the transcription of PDX-1, MafA, MafB and other transcriptional factors through the activation of the intracellular PI3K/Akt/FOXO1 signaling pathway on the surface of the cell surface GLP-1 receptor, and then promotes the transformation of the trans lineage of alpha cells into beta cells. [Objective] [Objective] to establish a diabetic rat model with severe beta cell injury induced by a single large dose of STZ. By observing the changes in the number of endocrine cells in the islets of rats after GLP-1 intervention, it is discussed whether GLP-1 can promote the in situ regeneration of islet beta cells in rats and the possible mechanism. GLP-1 receptor inhibitors and PI3K enzyme inhibitors are used. On the prognosis of diabetic rats, the transcriptional level of PI3K/Akt/FOXO1 signaling pathway and protein expression level were detected, and whether GLP-1 could promote the transformation of alpha cells into beta cells through PI3K/Akt/FOX01 signaling pathway was divided into the following three parts: the first part GLP-1 promoted the pancreatic islet beta cell in STZ induced diabetic rats Objective to investigate whether GLP-1 could promote the in situ regeneration of islet beta cells. Method a single large dose of STZ was used to establish a diabetic rat model, and the SD rats with fasting blood glucose greater than 28mmol/L were included in the study, and they were divided into five groups: normal control group, diabetic model group, GLP-150 g/kg intervention group, GLP-1100 u g/kg intervention group, GLP-12000 micron g/. Kg intervention group. The blood glucose and weight change were monitored every week. The ELISA method was used to detect the C peptide and insulin level. The number of endocrine cells was observed by insulin/gucagon double immunostaining in the pancreas section of the rat. The statistical method was one-way ANOVA, and the difference of P0.05 was statistically significant. Compared with the diabetes model group, the result of GLP-1 was the prognosis of diabetes. The blood glucose level of rats decreased, body weight decreased, C peptide, insulin level increased, the number of insulin secreting cells increased in a GLP-1 dose dependent type, and the difference was statistically significant (P0.05). Conclusion GLP-1 can promote in situ regeneration of beta cells. Second part GLP-1 promotes the islet's in situ redifferentiation through the transformation of alpha cells in the pancreatic island to beta cells. Objective to explore the possible mechanism of GLP-1 to promote the in situ regeneration of beta cells. Methods the first part was grouped with the first part of the rat pancreas frozen section with insulin/glucagon, insulin/amylase, insulin/Pan-CK double immunofluorescence staining. The PCNA immunohistochemical staining was performed on the paraffin section of the pancreas in rats. The statistical method was one-way ANOVA, P0.05. Results the difference was statistically significant. Results after GLP-1, insulin/glucagon double positive cells appeared in the islets of diabetic rats, the number increased with the increase of GLP-1 intervention dose, and the difference was statistically significant (P0.05). The insulin/amylase, insulin/pan-ck double positive cells were not observed in the pancreas slices of the rats, and the results of PCNA immunohistochemistry were not obvious. The difference (P0.05) and the staining area are located in the region of alpha cells. Conclusion GLP-1 promotes the in situ regeneration of beta cells from the transformation of alpha cells, no transformation of pancreatic acinar cells or ductal cells, and no self replication of alpha cells. The third part of GLP-1 and its receptors are up regulated by PDX-1 expression through the PI3K/Akt/ FOXO1 pathway to promote the transformation of alpha cells to beta cells. The purpose of the study was to explore the expression of PDX-1, MafB, and down regulation of MafA expression through its receptor through PI3K/Akt/FOXO1 pathway, and then to promote the conversion of MafA to beta cells. After establishing the diabetic rat model, the SD rats were divided into 7 groups: normal control group, diabetic model group, GLP-1 50 mu g/kg intervention group, GLP-1 100 u g/kg. Intervention group, GLP-1 200 g/kg intervention group, GLP-1 and GLP-1 receptor antagonist exendin (9-39) Co intervention group, GLP-1 and PI3K enzyme inhibitor LY294002 common intervention group.RT-PCR detection GLP-1R, AKT, PDX-1, concerned protein expression results. The results showed that the expression of GLP-1R, Akt, PDX-1, FOXO1, MafA, MafB in the diabetic model group was significantly lower than that in the normal group, and the expression of GLP-1R, Akt, PDX-1, FOXOl MafA was obviously increased, and the expression decreased. P-1 100 mu g/kg intervention group decreased, while MafB expression increased.LY294002 inhibition of PI3K enzyme, GLP-1R, Akt, PDX-1, Foxol, MafA mRNA expression was lower than that of GLP-1100. The K/Akt/FOXO1 pathway enhances the expression of transcription factor PDX-1 and MafA, down regulating the expression of MafB, thereby promoting the transformation of alpha cells into beta cells.
【學(xué)位授予單位】：南方醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R587.1

【參考文獻(xiàn)】

相關(guān)期刊論文 前3條

1 宋曉艷;何文俊;孫曉雅;郝好杰;韓為東;母義明;;胰高血糖素樣肽1對(duì)胰腺β細(xì)胞的作用及其機(jī)制[J];生物技術(shù)通訊;2015年04期

2 Akram T Kharroubi;Hisham M Darwish;;Diabetes mellitus: The epidemic of the century[J];World Journal of Diabetes;2015年06期

3 吳美芬;陳曉銘;武革;鄭坤杰;潘海燕;方爍;;2型糖尿病大鼠胰島β細(xì)胞PDX-1基因表達(dá)及GLP-1的干預(yù)作用[J];實(shí)用醫(yī)學(xué)雜志;2014年11期

，

本文編號(hào)：1955032